This activity is an enduring Webcast of the live Web conference series held in January and February 2012 for U.S.-based dialysis centers. Topics include:

• A summary of the recent changes to the CMS ESRD QIP
• Strategies to ensure more patients reach the new FDA-recommended Hb targets
• Solutions for successful QIP implementation at your dialysis center
• Real-life patient case scenarios that address changes to the CMS ESRD QIP
• A question and answer session with advice from faculty experts

This enduring activity is not available for CME or CNE credit.

Dialysis center team members:

• Nephrologists
• Nephrology nurses and nurse practitioners

Upon completion of this educational activity, participants should be able to:

• Summarize the recent changes to the CMS ESRD QIP structure and methodologies and their impact on anemia management
• Implement strategies to ensure successful treatment outcomes under the new FDA ESA labeling changes and the restructured CMS ESRD QIP
• Describe the clinical quality indicators and new safety reporting measures in the CMS ESRD QIP and the revised scoring system for these measures

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.

Steven Fishbane, MD (Activity Faculty)
Consultant: Affymax, Inc; Akebia Therapeutics, Inc; Rockwell Medical Inc
Speakers Bureau: AMAG Pharmaceuticals, Inc

Paula Dutka, RN, MSN, CNN (Activity Faculty)
Consultant: Affymax, Inc

Edward A. Alexander, MD (Course Director)
Nothing to disclose with regard to commercial support

Andrea M. Bernard, MSN/MBA, RN, CDN (Nurse Planner)
Nothing to disclose with regard to commercial support

Any off-label use was made known to the audience at the time of the meeting. If attendees participate in the discussion and include information on any pharmacologic therapy that is off-label, please announce this. Also, if participants could refrain from using trade names of drugs, it would be appreciated.

Educational Planning

Boston University School of Medicine
Ilana Hardesty and Julie White, MS
Nothing to disclose with regard to commercial support

Spire Learning
Jeanne Prater
Stockholder (spouse): Johnson & Johnson
Employee (spouse): Novo Nordisk

Christine Kocienda
Stockholder (spouse): Johnson & Johnson, Procter & Gamble

Jaime Symowicz, PhD
Nothing to disclose with regard to commercial support

DISCLAIMER

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

CONTINUING NURSING EDUCATION PROVIDER UNIT, BOSTON UNIVERSITY SCHOOL OF MEDICINE'S PROVIDER STATUS REFERS ONLY TO CONTINUING NURSING EDUCATION ACTIVITIES AND DOES NOT IMPLY THAT THERE IS REAL OR IMPLIED ENDORSEMENT BY CONTINUING NURSING EDUCATION PROVIDER UNIT, BOSTON UNIVERSITY SCHOOL OF MEDICINE OR ANCC OF ANY PRODUCT, SERVICE, OR COMPANY REFERRED TO IN THIS ACTIVITY NOR OF ANY COMPANY SUBSIDIZING COSTS RELATED TO THE ACTIVITY.